



Perspective

Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations

C.C. Heuvelings^{a,*}, S.G. de Vries^a, M.P. Grobusch^{a,b}^a Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands^b Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany

ARTICLE INFO

Article history:

Received 1 October 2016

Received in revised form 22 December 2016

Accepted 22 December 2016

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Keywords:

tuberculosis
identification
management
vulnerable populations
low-incidence countries

ABSTRACT

In low tuberculosis incidence regions, tuberculosis is mainly concentrated among hard-to-reach populations like migrants, homeless people, drug or alcohol abusers, prisoners and people living with HIV. To be able to eliminate tuberculosis from these low incidence regions tuberculosis screening and treatment programs should focus on these hard-to-reach populations. Here we discuss the barriers and facilitators of health care-seeking, interventions improving tuberculosis screening uptake and interventions improving treatment adherence in these hard-to-reach populations.

© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Tuberculosis (TB) remains a major public health issue worldwide. In low-incidence regions (<10 TB cases per 100,000 population) such as the European Union (EU), the United States (US), Australia, and Canada,¹ TB is mainly concentrated in vulnerable populations, such as migrants or foreign-born individuals,^{2–5} homeless people, drug or alcohol abusers, prisoners and people living with human immunodeficiency virus (HIV)^{2,3}; and TB is often clustered in big cities.⁶

Only limited surveillance data is available, as detection and reporting of TB cases is challenging in these vulnerable populations. In 2014, the 29 EU/EEA countries reported 58,008 TB cases, a notification rate of 11.9 cases per 100,000 population. Twenty-seven per cent of these TB cases were among migrants. In Cyprus, Iceland, Luxembourg, Malta, Norway and Sweden, more than 80% of the TB cases were reported among migrants, and in eight more countries migrants represented more than 50% of the TB cases.²

In the same year, the US reported a case-rate of 1.2 per 100,000 in US-born persons, compared to 15.4 per 100,000 for foreign-born persons, with the latter encompassing 66% of all cases.³ In Australia, incidence rates were highest among

foreign-born individuals as well (18.4 vs. 5.5 per 100,000 in 2013).⁴ In Canada, 69% of cases occurred in the foreign-born population with an incidence rate of 13.7 per 100,000 population, compared to 0.6 and 4.4 per 100,000 in Canadian-born non-Aboriginal people and nationwide, respectively.⁵ Transmission of TB from the migrant population to the native population seems to be low.⁷

As reported in 2014, of all the new TB cases in Europe, 2% were among prisoners, who had a relative risk of 9.6 to develop TB disease compared to the general population, as well as a higher risk of getting drug resistant TB.² In the US, 4.2% of the cases were among prisoners.³ Of all reported TB cases in the EU/EEA, the HIV status was known in 65%, of which 4.9% were co-infected with HIV.² In the US, 88.5% knew their HIV status, with 6.0% having been co-infected with HIV.³

The European Center of Disease Control and Prevention (ECDC) does not provide any TB data on homeless people nor on drug or alcohol abusers. The World Health Organization (WHO) reports TB rates among homeless people in industrialised countries to be up to 20 times higher compared to the general population; and that the TB risk among intravenous drug users increases with age, the number of years of drug use, and HIV status.⁸ In the US, 10.8% of cases reported excess alcohol use, 7.5% non-injecting drug use, 1.5% injecting drug use, and 5.6% of cases were reported as being homeless.³

Multidrug resistant TB (MDR-TB) is a growing problem worldwide, including in low incidence countries. In 2014, 4.0% of the EU/EEA TB cases with drug susceptibility testing (DST)

* Corresponding author: Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.

E-mail address: c.c.heuvelings@amc.uva.nl (C.C. Heuvelings).

results were MDR-TB (2.2% of all notified TB cases), with the highest percentages in the Baltic states (12–26% of the TB cases tested).² In the US 1.2%,³ in Canada 1.3%,⁹ and in Australia 2.0% of the TB cases undergoing DST were MDR-TB.⁴

The majority of the MDR-TB cases in low incidence countries are being diagnosed in the migrant population, mainly due to reactivation of latent TB. In the US and Australia around 85% of the MDR-TB cases were diagnosed among migrants.^{3,4} In the EU/EEA, 2.9% of migrant cases undergoing DST were diagnosed with MDR-TB.¹⁰

Against the backdrop of those data, the WHO and the European Respiratory Society developed an action framework to eliminate TB from low-incidence countries, with one of the priority actions to pre-eliminate TB being to address the most vulnerable populations described above.¹¹ ECDC published a guidance document on the control of TB in vulnerable and hard-to-reach populations,¹² based on three systematic reviews and expert opinion, discussing the barriers and facilitators for the uptake of TB care,¹³ as well as interventions to improve TB diagnosis and treatment among these populations.¹⁴

As TB is mainly clustered around vulnerable populations in low-incidence countries, it ought to be understood why TB care in these populations is so difficult, and what barriers and facilitators for the uptake of TB care exist.¹³ Misconceptions regarding susceptibility of TB are common, mainly among migrants,^{15–27} which is a factor delaying health care-seeking. In addition, stigma around TB is a major obstacle for initial health care-seeking, and subsequently for treatment adherence.^{15–17,19–21,23,26,28–33} Poor TB awareness among health care workers in low-incidence countries, lack of specialist services,^{15,17,29,34–37} and language/cultural barriers^{15,17,29,31,32,34,36,38} are reasons mentioned by the health-care providers for delayed diagnosis and impaired treatment adherence.

Secondly, it has been demonstrated that TB screening uptake improves once vulnerable populations are specifically accommodated.¹⁴ For example, it has been shown that the use of incentives increased screening uptake among homeless people^{39,40} and drug users.⁴¹ A mobile X-ray unit is also an effective tool to improve TB screening uptake among different vulnerable populations.^{42–44} Active referral to a TB clinic by providing a phone number, making an appointment, organising transport and sending reminders, improves screening uptake among migrants^{45,46} and drug users.^{47,48} Promoting TB screening and providing TB education by community health workers improves screening uptake and contact tracing among several vulnerable populations.^{49–51} Improved cooperation between several service providers, like street teams, drug services and health services, improves screening uptake among drug users.⁴⁸

Thirdly, effective screening methods to detect pulmonary TB among several vulnerable populations have to be determined.¹⁴ Screening by chest X-ray (CXR) is an effective and cost-effective intervention among all vulnerable populations.^{52–62} Adding sputum culture to CXR screening as a pre-migration screening tool for migrants from high-incidence countries increases the number of TB diagnoses in the home country and reduces the importation of TB into the host country.^{63–66} As spearheaded by non-affluent countries with a high burden of co-infections, collaborative TB/HIV prevention and treatment frameworks need to be further developed in order to reduce the burden of TB in people living with HIV, and to reduce the burden of HIV in people diagnosed with TB.⁶⁷

Last but not least, effective ways to improve treatment outcome and adherence need to be identified.¹⁴ Improved cooperation between key facilitators such as drug services and TB care providers enhances adherence to treatment among drug users.^{43,48,49,51} Enhanced case management increases treatment

adherence in several vulnerable populations.^{48,49,51} Directly observed therapy (DOT) improves treatment adherence and outcome in several vulnerable populations.^{68–71} Partial DOT, providing DOT during the first two months of treatment, could be as effective as full DOT.⁷² In low incidence countries, DOT provided at a convenient location did not yield any difference in treatment adherence compared to DOT provided at a TB clinic or hospital,⁷³ and again, the use of incentives improves treatment adherence among homeless people and drug users.^{71,74}

Studies evaluating integrated TB/HIV care are limited, even though the WHO recommends integrated TB/HIV care.⁶⁷ Simultaneous administration of TB treatment and antiretroviral therapy (ART) reduces mortality.⁶⁷ Knowledge of the HIV status of TB patients is essential, but in the EU/EEA, only 65% of the TB patients know their HIV status,² in the US 88.5%,³ and no figures have been published for Australia and Canada.^{4,5}

With the above-listed interventions, not all people living in the mentioned vulnerable populations are reached. A group of people that is not covered by these interventions are rough sleepers, as most homeless interventions are focused around shelters. A French study showed that screening and treating shelter users had a positive impact on rough sleepers as well.⁴⁴ Studies evaluating interventions to reach rough sleepers for TB screening should be conducted. The same accounts for intravenous drug users that do not use needle exchange programs or other drug services, but these two populations might have an overlap.

In countries where the focus of migrant screening is on pre-migration screening, refugees and illegal migrants could be missed. In light of the recent high influx of refugees from high TB incidence countries from the Middle East, Asia and Africa into Europe, this can prove to be problematic. The screening methods in refugee camps should be evaluated, and good collaboration between countries is essential to reduce the number of refugees not screened for TB. As most refugees do not stay in one place and may move to different locations frequently, the screening procedure should generate a rapid, reliable result. Therefore, sputum culture might not be the most effective intervention for this population. Whilst the GeneXpert MTB/RIF probably provides the quickest sputum result (less than 2 hours), has a better sensitivity than microscopy and can test for rifampicin susceptibility, the cost-effectiveness needs to be evaluated in the low incidence setting. Therefore, the WHO recommends the use of GeneXpert for patients with a high probability of MDR-TB (for example migrants from countries with high rates of MDR-TB, people previously treated for TB and contacts of MDR-TB cases) and HIV-associated TB.⁷⁵ Alternatively, sputum microscopy in addition to CXR screening might be the best option with DST for the detected TB cases.

Furthermore, TB treatment adherence and outcome and TB prevention are essential topics in these settings. Refugee camps and centers are overcrowded, increasing the risk of transmission. Tailored TB programs are needed,⁷⁶ taking TB knowledge, conceptions and the considerable burden of stigma into account.

Finally, with MDR-TB remaining a problem worldwide with a focus on migrants in low incidence countries,^{2,77} it is important to minimise the transmission of MDR-TB. A South African human-to-guinea pig transmission study showed that effective MDR-TB treatment reduces infectiousness rapidly⁷⁸; however, active case finding, sensitive screening methods, DST, screening contacts, starting effective treatment promptly, isolation of infectious patients, comprehensive TB infection control (see WHO guidelines⁷⁹), evaluation of co-morbidities (HIV, diabetes mellitus, viral hepatitis) and alcohol, drug and cigarette use, psychological care, and well organised continuation of care after hospital discharge⁸⁰ are important components for optimal patient management and

ought to be implemented to the highest possible level in the quest for pre-elimination of TB.

Conflict of interest

None of the authors has any conflict of interest to disclose.

Funding

The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval

Not required.

References

- World Health Organization (WHO). *Global Tuberculosis report 2015*. Geneva: WHO; 2015 (WHO/HTM/TB/2015.22).
- European Centre for Disease Prevention and Control (ECDC)/World Health Organization (WHO). *Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2016*. Stockholm: ECDC; 2016.
- Centers for Disease Control and Prevention (CDC). *Reported Tuberculosis in the United States*. Atlanta: CDC; 2014.
- Toms C, Stapledon R, Waring J, Douglas P. Tuberculosis notifications in Australia 2012 and 2013. *Commun Dis Intell* 2015;**39**(2):217–35.
- Public Health Agency of Canada. *Tuberculosis in Canada – Pre-release*. Ottawa (Canada): Minister of Public Works and Government Services Canada; 2016.
- de Vries G, Aldridge RW, Caylà JA, Haas WH, Sandgren A, van Hest NA, Abubakar I. Epidemiology of tuberculosis in big cities of the European Union and European Economic Area countries. *Euro Surveill* 2014;**19**:1–8.
- Sandgren A, Sane Schepisi M, Sotgiu G, Huitric E, Migliori GB, Manissero D, et al. Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. *Eur Resp J* 2014;**43**:1159–71.
- Figuerola-Munoz J, Ramon-Pardo P. *Tuberculosis control in vulnerable groups*. Geneva: World Health Organization; 2008.
- Public Health Agency of Canada. *Tuberculosis: Drug resistance in Canada 2014*. Ottawa (Canada): Minister of Public Works and Government Services Canada; 2015.
- Ködmön C, Zucs P, van der Werf MJ. Migration-related tuberculosis: epidemiology and characteristics of tuberculosis cases originating outside the European Union and European Economic Area, 2007 to 2013. *Euro Surveill* 2016;**21**(12). doi:<http://dx.doi.org/10.2807/1560-7917.es.2016.21.12.30164>.
- Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. *The European Respiratory Journal* 2015;**45**(4):928–52.
- European Centre for Disease Prevention and Control (ECDC). *Guidance on TB control in vulnerable and hard-to-reach populations*. Stockholm: ECDC; 2016.
- de Vries SG, Cremers AL, Heuvelings CC, Greve PF, Visser BJ, Belard S, et al. Barriers and facilitators for the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in low- and medium-incidence countries: A systematic review of qualitative literature. *Lancet Infect Dis* 2017.
- Heuvelings CC, de Vries SG, Greve PF, Visser BJ, Belard S, Janssen S, et al. Effectiveness of interventions aiming at identifying and managing tuberculosis among hard-to-reach populations: A systematic review. *Lancet Infect Dis* 2017.
- Gerrish K, Ismail M, Naisby A. *Tackling TB. together: a community participatory study of the socio-cultural factors influencing an understanding of TB within the Somali community in Sheffield*. Sheffield: Sheffield Hallam University; 2010.
- Gerrish K, Naisby A, Ismail M. The meaning and consequences of tuberculosis among Somali people in the United Kingdom. *J Adv Nurs* 2012;**68**:2654–63.
- Gerrish K, Naisby A, Ismail M. Experiences of the diagnosis and management of tuberculosis: a focused ethnography of Somali patients and healthcare professionals in the UK. *J Adv Nurs* 2013;**69**:2285–94.
- Johnson A. *Beliefs and barriers related to understanding TB amongst vulnerable groups in South East London*. London: Health Protection Agency; 2006.
- Gibson N, Cave A, Doering D, Ortiz L, Harms P. Socio-cultural factors influencing prevention and treatment of tuberculosis in immigrant and Aboriginal communities in Canada. *Soc Sci Med* (1982) 2005;**61**:931–42.
- van der Oest C, Chenhall R, Hood D, Kelly P. Talking about TB: multicultural diversity and tuberculosis services in Waikato, New Zealand. *N Z Med J* 2005;**118**:U1496.
- Nnoaham KE, Pool R, Bothamley G, Grant AD. Perceptions and experiences of tuberculosis among African patients attending a tuberculosis clinic in London. *Int J Tuberc Lung Dis* 2006;**10**:1013–7.
- Vukovic DS, Nagorni-Obradovic LM. Knowledge and awareness of tuberculosis among Roma population in Belgrade: a qualitative study. *BMC Infect Dis* 2011;**11**:284.
- Coreil J, Mayard G, Simpson KM, Lauzardo M, Zhu Y, Weiss M. Structural forces and the production of TB-related stigma among Haitians in two contexts. *Soc Sci Med* 2010;**71**:1409–17.
- West EL, Gadkowski LB, Ostbye T, Piedrahita C, Stout JE. Tuberculosis knowledge, attitudes, and beliefs among North Carolinians at increased risk of infection. *N C Med J* 2008;**69**:14–20.
- Houston HR, Harada N, Makinodan T. Development of a culturally sensitive educational intervention program to reduce the high incidence of tuberculosis among foreign-born Vietnamese. *Ethn Health* 2002;**7**:255–65.
- Yamada S, Caballero J, Matsunaga DS, Agustin G, Magana M. Attitudes regarding tuberculosis in immigrants from the Philippines to the United States. *Fam Med* 1999;**31**:477–82.
- Fujiwara PI. Tide pools: what will be left after the tide has turned? *Int J Tuberc Lung Dis* 2000;**4**:S111–6.
- Sagbakken M, Bjune GA, Frich JC. Experiences of being diagnosed with tuberculosis among immigrants in Norway—factors associated with diagnostic delay: a qualitative study. *Scand J Public Health* 2010;**38**:283–90.
- Sagbakken M, Bjune GA, Frich JC. Humiliation or care? A qualitative study of patients' and health professionals' experiences with tuberculosis treatment in Norway. *Scand J Caring Sci* 2012;**26**:313–23.
- Zuniga JA, Munoz SE, Johnson MZ, Garcia A. Tuberculosis treatment for Mexican Americans living on the U.S. -Mexico border. *J Nurs Scholarsh* 2014;**46**:253–62.
- Bender A, Andrews G, Peter E. Displacement and tuberculosis: recognition in nursing care. *Health Place* 2010;**16**:1069–76.
- Knowledge, perceptions and barriers and the social meaning of tuberculosis among asylum seekers, homeless people and refugee communities in Brent 2004–2006*. London: Brent Refugee Forum; 2007.
- Whoolery M. *Survivalising among homeless people with tuberculosis: a grounded theory study*. UK: Faculty of Society and Health Bucks New University, Brunel University; 2008.
- Wannheden C, Westling K, Savage C, Sandahl C, Ellenius J. HIV and tuberculosis coinfection: a qualitative study of treatment challenges faced by care providers. *Int J Tuberc Lung Dis* 2013;**17**:1029–35.
- Jackson L, Yuan L. Family physicians managing tuberculosis. Qualitative study of overcoming barriers. *Can Fam Physician* 1997;**43**:649–55.
- Moro ML, Resi D, Lelli B, Nicoli A, Gagliotti C, Falcone F. Barriers to effective tuberculosis control: a qualitative study. *Int J Tuberc Lung Dis* 2005;**9**:1355–60.
- Belling R, Woods L, Boudioni M, McLaren S. *Pan London Tuberculosis services: An audit evaluation*. Institute for Strategic Leadership and Improvement. London: London South Bank University; 2008.
- Marais F. *Towards the improvement of tuberculosis control and participatory research: A multi-method Community-based Participatory Research study of TB in migrant African communities in the borough of Westminster*. London: London: Imperial College, Department of Primary Care and Social Medicine; 2007.
- Citron KM, Southern A, Dixon M. *Out of the shadow Detecting and treating tuberculosis amongst single homeless people*. London: Crisis; 1995. (last accessed September 2016) <http://www.crisis.org.uk/publications-search.php?fullitem=164>.
- Pilote L, Tulsy JP, Zolopa AR, Hahn JA, Schechter GF, Moss AR. Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. *Arch Intern Med* 1996;**156**:161–5.
- Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des Jarlais DC. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. *J Urban Health* 2001;**78**:550–67.
- Story A, Aldridge RW, Abubakar I, Stagg HH, Lipman M, Watson JM, Hayward AC. Active case finding for pulmonary tuberculosis using mobile digital chest radiography: an observational study. *Int J Tuberc Lung Dis* 2012;**16**:1461–7.
- Jit M, Stagg H, Aldridge R, White P, Abubakar I. Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. *BMJ* 2011;**343**:d5376.
- Bernard C, Sougakoff W, Fournier A, Larnaudie S, Antoun F, Robert J, et al. Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris. *Int J Tuberc Lung Dis* 2012;**16**:649–55.
- Harstad I, Henriksen AH, Sagvik E. Collaboration between municipal and specialist public health care in tuberculosis screening in Norway. *BMC Health Services Research* 2014;**14**:238.
- Bell TR, Molinari NM, Blumensaadt S, Selent MU, Arbisí M, Shah N, et al. Impact of port of entry referrals on initiation of follow-up evaluations for immigrants with suspected tuberculosis: Illinois. *J Immigr Minor Health* 2013;**15**:673–9.
- Ruutel K, Loit HM, Sepp T, Kliiman K, McNutt LA, Uuskula A. Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial. *BMC Res Notes* 2011;**4**:192.
- Duarte R, Santos A, Mota M, Carvalho A, Marques A, Barros H. Involving community partners in the management of tuberculosis among drug users. *Public Health* 2011;**125**:60–2.
- Goetsch U, Bellinger OK, Buettel KL, Gottschalk R. Tuberculosis among drug users and homeless persons: impact of voluntary X-ray investigation on active case finding. *Infection* 2012;**40**:389–95.
- Ospina JE, Orcau A, Millet JP, Sanchez F, Casals M, Cayla JA. Community health workers improve contact tracing among immigrants with tuberculosis in Barcelona. *BMC public health* 2012;**12**:158.
- Ricks PM. *Tuberculosis control among substance users: The indigenous leadership outreach model vs. standard care*. University of Illinois at Chicago; 2008.

52. Mor Z, Leventhal A, Weiler-Ravell D, Peled N, Lerman Y. Chest radiography validity in screening pulmonary tuberculosis in immigrants from a high-burden country. *Respir Care* 2012;**57**:1137–44.
53. Mor Z, Weinstein O, Tischler-Aurkin D, Leventhal A, Alon Y, Grotto I. The yield of tuberculosis screening of undocumented migrants from the Horn of Africa based on chest radiography. *Isr Med Assoc J* 2015;**17**:11–3.
54. Verver S, Bwire R, Borgdorff MW. Screening for pulmonary tuberculosis among immigrants: estimated effect on severity of disease and duration of infectiousness. *Int J Tuberc Lung Dis* 2001;**5**:419–25.
55. Monney M, Zellweger JP. Active and passive screening for tuberculosis in Vaud Canton, Switzerland. *Swiss Med Wkly* 2005;**135**:469–74.
56. Laifer G, Widmer AF, Simcock M, Bassetti S, Trampuz A, Frei R, et al. TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents. *Am J Med* 2007;**120**:350–6.
57. Puisis M, Feinglass J, Lidow E, Mansour M. Radiographic screening for tuberculosis in a large urban county jail. *Public Health Rep* 1996;**111**:330–4.
58. Jones TF, Schaffner W. Miniature chest radiograph screening for tuberculosis in jails: a cost-effectiveness analysis. *Am J Respir Crit Care Med* 2001;**164**:77–81.
59. Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. *Am J Respir Crit Care Med* 2000;**162**:2079–86.
60. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. *Am J Respir Crit Care Med* 2000;**161**:780–9.
61. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, et al. Domestic returns from investment in the control of tuberculosis in other countries. *N Engl J Med* 2005;**353**:1008–20.
62. Mor Z, Lerman Y, Leventhal A. Pre-immigration screening process and pulmonary tuberculosis among Ethiopian migrants in Israel. *Eur Respir J* 2008;**32**:413–8.
63. Lowenthal P, Westenhouse J, Moore M, Posey DL, Watt JP, Flood J. Reduced importation of tuberculosis after the implementation of an enhanced pre-immigration screening protocol. *Int J Tuberc Lung Dis* 2011;**15**:761–6.
64. Assael R, Cervantes J, Barrera G. Smears and cultures for diagnosis of pulmonary tuberculosis in an asymptomatic immigrant population. *Int J Gen Med* 2013;**6**:777–9.
65. Posey DL, Naughton MP, Willacy EA, Russell M, Olson CK, Godwin CM, et al. Implementation of new TB screening requirements for U.S.-bound immigrants and refugees – 2007–2014. *MMWR* 2014;**63**:234–6.
66. Liu Y, Posey DL, Cetron MS, Painter JA. Effect of a Culture-Based Screening Algorithm on Tuberculosis Incidence in Immigrants and Refugees Bound for the United States: A Population-Based Cross-sectional Study. *Ann Intern Med* 2015;**162**:420–8.
67. World Health Organisation (WHO). *WHO Policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders*. Geneva: WHO; 2012 (WHO/HTM/TB/2012.1).
68. Chemtob D, Leventhal A, Berlowitz Y, Weiler-Ravell D. The new National Tuberculosis Control Programme in Israel, a country of high immigration. *Int J Tuberc Lung Dis* 2003;**7**:828–36.
69. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. *AIDS* 1994;**8**:1103–8.
70. Rodrigo T, Cayla JA, Garcia de Olalla P, Brugal MT, Jansà JM, Guerrero R, et al. Effectiveness of tuberculosis control programmes in prisons, Barcelona 1987–2000. *Int J Tuberc Lung Dis* 2002;**6**:1091–7.
71. Juan G, Lloret T, Perez C, Lopez P, Navarro R, Ramón M, Cortijo J. Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. *Int J Tuberc Lung Dis* 2006;**10**:215–21.
72. Dèruaz J, Zellweger JP. Directly observed therapy for tuberculosis in a low prevalence region: first experience at the Tuberculosis Dispensary in Lausanne. *Swiss Med Wkly* 2004;**134**:552–8.
73. MacIntyre CR, Goebel K, Brown GV, Skull S, Starr M, Fullinwar RO. A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting. *Int J Tuberc Lung Dis* 2003;**7**:848–54.
74. Bock NN, Sales RM, Rogers T, DeVoe B. A spoonful of sugar . . . : improving adherence to tuberculosis treatment using financial incentives. *Int J Tuberc Lung Dis* 2001;**5**:96–8.
75. World Health Organisation (WHO). *Xpert MTB/RIF implementation manual: technical and operational 'how-to'; practical considerations*. Geneva: WHO; 2014 (WHO/HTM/TB/2014.1).
76. Abubakar I, Thomas HL, Morgan M, Anderson S, Zenner D, Cosford P. A collaborative strategy to tackle tuberculosis in England. *Lancet* 2015;**385**:312–3.
77. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. *Thorax* 2006;**61**:158–63.
78. Dharmadhikari AS, Mphahlele M, Venter K, Stolz A, Mathebula R, Masotla T, et al. Rapid impact of effective treatment on transmission of multidrug resistant tuberculosis. *Int J Tuberc Lung Dis* 2014;**18**(9):1019–25. doi:<http://dx.doi.org/10.5588/ijtld.13.0834>.
79. World Health Organisation (WHO). *WHO policy on TB infection control in health-care facilities, congregate settings and households*. Geneva: WHO; 2009 (WHO/HTM/TB/2009.419).
80. Lange C, Abubakar I, Alffenaar J, Bothamley G, Caminero JA, Carvalho ACC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. *Eur Respir J* 2014;**44**:23–63.